Mundipharma Strikes Deal For Prestige's Trastuzumab
Mundipharma has struck a deal with Prestige BioPharma for rights to the Singapore-based firm’s biosimilar trastuzumab in selected European markets.
Mundipharma has struck a deal with Prestige BioPharma for rights to the Singapore-based firm’s biosimilar trastuzumab in selected European markets.